Notably, IDO1 inhibitors have already entered clinical trials, combined first with chemotherapeutic drugs and then with immune check-point inhibitors, such as anti-CTLA-4 and/or PD-1, to turn melanoma tolerance into anti-melanoma immunity [24]. Here, IDO1 is linked to melanoma.